Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrauterine exosome therapy for severe early-onset fetal growth restriction
IRCT20140317017034N10Phase 2Recruiting
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Nov 2024
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of umbilical cord-derived exosomes in intrauterine growth restriction (IUGR) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Fetal weight, Utero-fetal-placental Dopplers and 8 more. Started Nov 2024; status: recruiting.
02
Drugs
umbilical cord-derived exosomes
03
Conditions
intrauterine growth restriction (IUGR)
Beyond the preview
Go deeper on IRCT20140317017034N10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140317017034N10.